Immunodiagnostic Systems Share Discussion Threads

[philmiboots] 28/12/2004 19:47

Thanks PUGUGLY, header updated.

Timesonline-

Immunodiagnostic Systems, which makes diagnostic testing kits, made a solid debut on AIM, closing at 55p after a Teather & Greenwood placing at 51p, which valued the company at £6.75 million.

[pugugly] 28/12/2004 10:48

Full details missing from AIM announcement

but header shareholding appears to relate to pre admission. Details of post admission form above wire statement below.

Pre admission Post admission
Percentage Percentage

3i 28.98% 18.94%
Roger Duggan 22.75% 18.08%
Paul Hailes 13.92% 10.71%
David Laurie 13.92% 10.34%
James Stoker 10.00% 7.43%
New Star Asset Management - 6.67%
IDS Limited - Employee Benefit Trust 4.54% 3.37%
Paul Puntin 4.21% 3.13%

Not sure how much interest thsi will create, Need to know far more about capital structure etc.

[double6] 26/12/2004 21:05

Shares tightly held...

[_dan_] 24/12/2004 18:24

A fast growing biotech company which will speed tests for the deadly MRSA superbug will today float on the stock market in a bid to raise nearly £2m.
Boldon-based Immunodiagnositc Systems yesterday...........





dan

[philmiboots] 24/12/2004 17:27

Listed today on AIM:- Immunodiagnostic Systems Holdings plc              Website: Immunodiagnostic Systems Holdings PLC (IDS) is a producer of diagnostic testing kits for the clinical and research markets, focusing on immunoassays used in the area of bone disease (for example, Vitamin D and bone formation/loss markers).It designs, manufactures and sells immunoassay kits, which are used to measure or detect particular substances within a sample, thus aiding the diagnosis or monitoring of a disease or providing information for research studies. IDS manufactures its own tests and distributes these, along with other manufacturers' tests, directly in the United Kingdom, France, Germany and the United States, and through third-party distributors in other territories. Its product areas include Vitamin D immunoassays, Octeia, SBA - Trap kits (RatTrap, MouseTRAP, and human BoneTRAP) and Gamma B. In July 2007, IDS completed the acquisition of Nordic Bioscience Diagnostics A/S.   Major Shareholders (24/12/04) 13,237,703 shares in issue 3i 18.94% Roger Duggan 18.08% Paul Hailes 10.71% David Laurie 10.34% James Stoker 7.43% New Star Asset Management 6.67% IDS Employee Benefit Trust 3.37% Paul Puntin 3.13%